PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2003 March; 4(1): 18–26.
Published online 2003 January 3. doi:  10.1208/pt040103
PMCID: PMC2750299

Studies in formulation and pharmacotechnical evaluation of controlled release transdermal delivery system of bupropion

Abstract

The objective of the present study was to design and evaluate unilaminate transdermal adhesive matrix systems capable of diffusing bupropion base at a constant rate over an extended period of time as an alternative route of administration. Unilaminate transdermal adhesive matrices have been fabricated with different concentrations of Eudragit E as the adhesive and rate-controlling polymer. The in vitro release and epidermal flux through human cadaver skin were studied. The release of drug from the matrices obeyed zero order release kinetics (r2=0.9810 to 0.9960). The delivery rate of bupropion ranged from 10.5 mg to 31.4 mg per day from a 3.14 cm2 area of matrix. The relation between concentration of bupropion base in matrix and epidermal flux, concentration of drug in matrix, and epidermal adsorption of bupropion during diffusion follow hyperbolic fashion. Triethylcitrate (TEC) and dibutylphthalate (DBP) have no influence on the diffusion of bupropion through human cadaver skin when used as plasticizers. Incorporation of succinic acid in the adhesive matrix retarded diffusion due to the formation of rigid cross linking of the polymer, while propylene glycol and myristic acid, alone or in combination, significantly enhanced the flux of bupropion through human cadaver skin.

Keywords: unilaminate transdermal adhesive matrix, bupropion free base, in vitro release study, epidermal flux, plasticizers, release modifiers

Full Text

The Full Text of this article is available as a PDF (79K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Laizure SC. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther. 1985;38:586–589. [PubMed]
2. Sweet RA. Pharmacokinetics of single and multiple dose bupropion in elderly patients with depression. J Clin Pharmacol. 1995;35:875–884. [PubMed]
3. Goldberg-Cettina M, Liu P, Nightingle J, Kurihora-Bergstrom T. Enhanced transdermal delivery of estradiol in vitro using binary vehicles of isopropyl myristate and short chain alkanols. In J Pharm. 1995;114:237–245.
4. Chien YW. Rate-control drug delivery system: controlled release versus sustained release. Med Prog Tech. 1989;15:21–46. [PubMed]
5. Yu JW, Chien TY, Chien YW. Transdermal dual controlled delivery of testosterone and estradiol: impact of system design. Drug Dev Ind Pharm. 1991;17:1883–1904. doi: 10.3109/03639049109048057. [Cross Ref]
6. Chien YW. Concept and system design for the rate controlled drug delivery. In: Chien YW, editor. Novel Drug Delivery Systems. 2nd ed. New York, NY: Marcel Dekker, Inc; 1992. pp. 1–42.
7. Loth H. Vehicular influence on transdermal drug penetration. Int J Pharm. 1991;68:1–10. doi: 10.1016/0378-5173(91)90120-D. [Cross Ref]
8. Stantus GC, Baker RW. Transdermal enhancer patent literature. J Control Release. 1993;25:1–20. doi: 10.1016/0168-3659(93)90090-R. [Cross Ref]
9. Barrickman LL. Bupropion versus methylphenidate in the treatment of attention-deficit hypersensitivity disorder. J Am Acad Adoles Psychiatry. 1995;34(5):649–657. [PubMed]
10. Lehman K. Chemistry and application properties of polyme-thacrylate coating systems. In: Meginigy JW, editor. Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms. New York, NY: Marcel Dekker, Inc; 1989. pp. 101–176.
11. Peppas KA, Meadows DL. Macromolecular structure and solute diffusion in membranes: an overview of recent theories. J Membrane Sci. 1982;16:361–377. doi: 10.1016/S0376-7388(00)81321-6. [Cross Ref]
12. Raffiee-Tehrani M, Safaii-Nikui N, Toliat T, Petereit H, Beckert T. Acrylic resins as rate controlling membranes in delivery unilaminate device of estradiol. 25th Int Symp Controlled Release Bioact. Mater. 1998:28–29.
13. Raffiee-Tehrani M, Safaii-Nikui N, Toliat T, Petereit H, Beckert T. Effect of plasticizers and enhancers on release behavior of estradiol from unilaminate TDD patch. 26th Int Symp Controlled Release Bioact Mater. 1999:455–456.
14. Poulsen BJ, Young E, Coquilla V, Katz M. Effect of topical vehicle composition on the in vitro release of fluocinolone acetonide and its acetate esters. J Pharm Sci. 1968;57:928–933. doi: 10.1002/jps.2600570603. [PubMed] [Cross Ref]
15. Cooper ER. Increased skin permeability for lipophilic molecules. J Pharm Sci. 1984;73:1153–1156. doi: 10.1002/jps.2600730831. [PubMed] [Cross Ref]
16. Aungst BJ, Blake JA, Rogers NJ, Hussain MA. Transdermal oxymorphine formulation development and methods for evaluating flux and lag times for two skin enhancing vehicles. J Pharm Sci. 1990;79:1072–1076. doi: 10.1002/jps.2600791207. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists